Fusemachines launches website for AI Twin technology

Fusemachines Inc. (NASDAQ: FUSE) said existing investor Meteora Capital added $2.5 million via a convertible note with a fixed $4.20 per share conversion price, plus 2.05 million warrants exercisable at $4.20. If all warrants are exercised, Fusemachines could receive up to $8.61 million more, totaling $10.66 million. Proceeds will fund its Agentic AI platform development and commercialization.

Pfizer's phase 2 trial for its pediatric pneumonia vaccine showed a strong immune response against all 25 serotypes. The vaccine also demonstrated safety and tolerability, according to the company.

Pfizer and Valneva's Lyme disease vaccine, LB6V, showed 73.2% efficacy in a phase 3 trial but missed its primary endpoint. The vaccine targets six common serotypes of B. burgdorferi. The trial involved nearly 10,000 participants. Lyme disease affects around 476,000 people annually in the U.S. according to the CDC.

Pfizer presented Phase 2 data for its 25-strain infant pneumococcal vaccine, PF-07872412, showing immune responses and safety. The study involved 401 infants, with no serious adverse events reported. Larger trials are ongoing. Pfizer shares closed at $30.03 on Oct. 23, before the presentation.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced mortality risk by 58% in a lung cancer trial. Imdelltra's US list price is around $300,000 per cycle. Analysts project annual revenues exceeding $2.5B by 2030. The drug is approved for extensive-stage small cell lung cancer, with 80% of trial patients alive at one year.

Pfizer announced Phase 2 study results for its 25-valent pneumococcal vaccine candidate, PF-07872412, showing robust immune responses against all 25 serotypes in infants, comparable safety to PREVNAR 20, and enhanced response to serotype 3. The vaccine also demonstrated functional responses in an OPA assay. Phase 3 studies are ongoing, with plans for a 35-valent vaccine in adults by 2026.